Artelo Biosciences is a clinical-stage biopharmaceutical company focused on modulating lipid-signaling pathways to treat cancer, pain, and neurological conditions. The company's pipeline is anchored by ART27.13, a peripherally selective synthetic cannabinoid for cancer-related anorexia and cachexia, and ART26.12, a novel FABP5 inhibitor for neuropathic pain. While early clinical data for both assets are promising—including positive Phase 1 safety data for ART26.12 and encouraging weight-gain signals in the Phase 2 CAReS trial for ART27.13—the company remains pre-revenue and highly dependent on capital markets or strategic partnerships to fund its clinical trials. A recent capital raise has temporarily extended the cash runway into late 2026, but ongoing dilution risks and the early-stage nature of the pipeline warrant a cautious Hold recommendation until clear clinical readouts or strategic partnerships materialize.